9.8 USD
-0.13 (-1.31%)
9.8 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to FOLD. FOLD was compared to 534 industry peers in the Biotechnology industry. FOLD has an average financial health and profitability rating. FOLD has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year FOLD has reported negative net income.
In the past year FOLD had a positive cash flow from operations.
In the past 5 years FOLD always reported negative net income.
In the past 5 years FOLD always reported negative operating cash flow.
1.2 Ratios
FOLD has a Return On Assets of -1.62%. This is amongst the best in the industry. FOLD outperforms 88.76% of its industry peers.
Looking at the Return On Equity, with a value of -6.10%, FOLD belongs to the top of the industry, outperforming 90.07% of the companies in the same industry.
FOLD's Return On Invested Capital of 4.07% is amongst the best of the industry. FOLD outperforms 91.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.62% | ||
| ROE | -6.1% | ||
| ROIC | 4.07% |
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
FOLD's Operating Margin of 5.77% is amongst the best of the industry. FOLD outperforms 90.26% of its industry peers.
With an excellent Gross Margin value of 89.77%, FOLD belongs to the best of the industry, outperforming 91.39% of the companies in the same industry.
In the last couple of years the Gross Margin of FOLD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.77% | ||
| PM (TTM) | N/A | ||
| GM | 89.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
2. Health
2.1 Basic Checks
FOLD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
FOLD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, FOLD has more shares outstanding
FOLD has a better debt/assets ratio than last year.
2.2 Solvency
FOLD has an Altman-Z score of -0.22. This is a bad value and indicates that FOLD is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of FOLD (-0.22) is comparable to the rest of the industry.
FOLD has a debt to FCF ratio of 40.45. This is a negative value and a sign of low solvency as FOLD would need 40.45 years to pay back of all of its debts.
The Debt to FCF ratio of FOLD (40.45) is better than 89.70% of its industry peers.
FOLD has a Debt/Equity ratio of 1.70. This is a high value indicating a heavy dependency on external financing.
FOLD has a worse Debt to Equity ratio (1.70) than 79.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.7 | ||
| Debt/FCF | 40.45 | ||
| Altman-Z | -0.22 |
ROIC/WACC0.44
WACC9.28%
2.3 Liquidity
A Current Ratio of 2.99 indicates that FOLD has no problem at all paying its short term obligations.
With a Current ratio value of 2.99, FOLD is not doing good in the industry: 63.11% of the companies in the same industry are doing better.
FOLD has a Quick Ratio of 2.09. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.09, FOLD is not doing good in the industry: 72.47% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.99 | ||
| Quick Ratio | 2.09 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 91.18% over the past year.
FOLD shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.28%.
The Revenue has been growing by 23.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)91.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%400%
Revenue 1Y (TTM)21.28%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%19.46%
3.2 Future
Based on estimates for the next years, FOLD will show a very strong growth in Earnings Per Share. The EPS will grow by 69.00% on average per year.
Based on estimates for the next years, FOLD will show a quite strong growth in Revenue. The Revenue will grow by 19.14% on average per year.
EPS Next Y73.29%
EPS Next 2Y89.17%
EPS Next 3Y71.81%
EPS Next 5Y69%
Revenue Next Year19.05%
Revenue Next 2Y20.13%
Revenue Next 3Y19.68%
Revenue Next 5Y19.14%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
FOLD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
FOLD is valuated quite expensively with a Price/Forward Earnings ratio of 34.49.
90.82% of the companies in the same industry are more expensive than FOLD, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 36.21. FOLD is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 34.49 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, FOLD is valued cheaply inside the industry as 90.07% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, FOLD is valued cheaply inside the industry as 90.26% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 312 | ||
| EV/EBITDA | 74.04 |
4.3 Compensation for Growth
FOLD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
FOLD's earnings are expected to grow with 71.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y89.17%
EPS Next 3Y71.81%
5. Dividend
5.1 Amount
FOLD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
9.8
-0.13 (-1.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners101.58%
Inst Owner Change-1.7%
Ins Owners0.6%
Ins Owner Change1.32%
Market Cap3.02B
Revenue(TTM)598.70M
Net Income(TTM)-14.06M
Analysts84.71
Price Target16.32 (66.53%)
Short Float %5.75%
Short Ratio3.26
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.12%
Min EPS beat(2)41.73%
Max EPS beat(2)52.51%
EPS beat(4)3
Avg EPS beat(4)76.91%
Min EPS beat(4)-26.06%
Max EPS beat(4)239.47%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.57%
Min Revenue beat(2)0.02%
Max Revenue beat(2)3.12%
Revenue beat(4)2
Avg Revenue beat(4)-1.83%
Min Revenue beat(4)-9.62%
Max Revenue beat(4)3.12%
Revenue beat(8)4
Avg Revenue beat(8)-0.79%
Revenue beat(12)8
Avg Revenue beat(12)-0.1%
Revenue beat(16)9
Avg Revenue beat(16)-1.08%
PT rev (1m)1.73%
PT rev (3m)0.63%
EPS NQ rev (1m)17.07%
EPS NQ rev (3m)28.58%
EPS NY rev (1m)8.34%
EPS NY rev (3m)16.82%
Revenue NQ rev (1m)-0.96%
Revenue NQ rev (3m)-1.29%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 34.49 | ||
| P/S | 5.05 | ||
| P/FCF | 312 | ||
| P/OCF | 233.01 | ||
| P/B | 13.12 | ||
| P/tB | 169.07 | ||
| EV/EBITDA | 74.04 |
EPS(TTM)-0.03
EYN/A
EPS(NY)0.28
Fwd EY2.9%
FCF(TTM)0.03
FCFY0.32%
OCF(TTM)0.04
OCFY0.43%
SpS1.94
BVpS0.75
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.62% | ||
| ROE | -6.1% | ||
| ROCE | 5.15% | ||
| ROIC | 4.07% | ||
| ROICexc | 6.72% | ||
| ROICexgc | 14.09% | ||
| OM | 5.77% | ||
| PM (TTM) | N/A | ||
| GM | 89.77% | ||
| FCFM | 1.62% |
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
F-Score5
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.7 | ||
| Debt/FCF | 40.45 | ||
| Debt/EBITDA | 9.31 | ||
| Cap/Depr | 43.2% | ||
| Cap/Sales | 0.55% | ||
| Interest Coverage | 0.78 | ||
| Cash Conversion | 30.81% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.99 | ||
| Quick Ratio | 2.09 | ||
| Altman-Z | -0.22 |
F-Score5
WACC9.28%
ROIC/WACC0.44
Cap/Depr(3y)68.89%
Cap/Depr(5y)61.13%
Cap/Sales(3y)1.23%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)91.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%400%
EPS Next Y73.29%
EPS Next 2Y89.17%
EPS Next 3Y71.81%
EPS Next 5Y69%
Revenue 1Y (TTM)21.28%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%19.46%
Revenue Next Year19.05%
Revenue Next 2Y20.13%
Revenue Next 3Y19.68%
Revenue Next 5Y19.14%
EBIT growth 1Y139.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year134.62%
EBIT Next 3Y105.52%
EBIT Next 5YN/A
FCF growth 1Y105.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y108.46%
OCF growth 3YN/A
OCF growth 5YN/A
AMICUS THERAPEUTICS INC / FOLD FAQ
What is the fundamental rating for FOLD stock?
ChartMill assigns a fundamental rating of 4 / 10 to FOLD.
What is the valuation status of AMICUS THERAPEUTICS INC (FOLD) stock?
ChartMill assigns a valuation rating of 5 / 10 to AMICUS THERAPEUTICS INC (FOLD). This can be considered as Fairly Valued.
What is the profitability of FOLD stock?
AMICUS THERAPEUTICS INC (FOLD) has a profitability rating of 4 / 10.
What is the financial health of AMICUS THERAPEUTICS INC (FOLD) stock?
The financial health rating of AMICUS THERAPEUTICS INC (FOLD) is 4 / 10.